Jivi (Antihemophilic Factor [Recombinant, B-domain deleted, PEGylated]) is indicated in previously treated adults and adolescents (≥12 years of age) with hemophilia A (congenital Factor VIII deficiency) for:

• Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes
• Control and prevention of episodic bleeding
• Peri-operative management of bleeding (surgical prophylaxis)

Jivi does not contain von Willebrand factor and is not indicated for the treatment of von Willebrand disease.

Safety and efficacy for previously untreated patients (PUPs) have not been studied.

Click here for additional safety information and a link to the product monograph discussing:¹

• Contraindications in patients who have had prior anaphylactic reaction to this drug or its components, or to mouse or hamster protein
• Relevant warnings and precautions regarding percutaneous puncture with a needle contaminated with blood transmitting infectious viruses including HIV (AIDS) and hepatitis, considering the risk of central venous access device (CVAD)-related complications if a CVAD is required, hypersensitivity reactions, including anaphylaxis, immune response associated with anti-polyethylene glycol (PEG), manifested as symptoms of acute hypersensitivity and/or loss of drug effect, monitoring plasma Factor VIII activity and for the formation of neutralizing antibodies (inhibitors) to Factor VIII, pregnant women, nursing women and geriatric patients
• Conditions of clinical use, adverse reactions and dosing instructions

Click on the options below to learn more.